Literature DB >> 22154545

Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.

Jane L Hurwitz1, Izabela Stasik, Emma M Kerr, Caitriona Holohan, Kelly M Redmond, Kirsty M McLaughlin, Sara Busacca, Dario Barbone, V Courtney Broaddus, Steven G Gray, Ken J O'Byrne, Patrick G Johnston, Dean A Fennell, Daniel B Longley.   

Abstract

INTRODUCTION: Malignant pleural mesothelioma (MPM) is a rapidly fatal malignancy that is increasing in incidence. The caspase 8 inhibitor FLIP is an anti-apoptotic protein over-expressed in several cancer types including MPM. The histone deacetylase (HDAC) inhibitor Vorinostat (SAHA) is currently being evaluated in relapsed mesothelioma. We examined the roles of FLIP and caspase 8 in regulating SAHA-induced apoptosis in MPM.
METHODS: The mechanism of SAHA-induced apoptosis was assessed in 7 MPM cell lines and in a multicellular spheroid model. SiRNA and overexpression approaches were used, and cell death was assessed by flow cytometry, Western blotting and clonogenic assays.
RESULTS: RNAi-mediated FLIP silencing resulted in caspase 8-dependent apoptosis in MPM cell line models. SAHA potently down-regulated FLIP protein expression in all 7 MPM cell lines and in a multicellular spheroid model of MPM. In 6/7 MPM cell lines, SAHA treatment resulted in significant levels of apoptosis induction. Moreover, this apoptosis was caspase 8-dependent in all six sensitive cell lines. SAHA-induced apoptosis was also inhibited by stable FLIP overexpression. In contrast, down-regulation of HR23B, a candidate predictive biomarker for HDAC inhibitors, significantly inhibited SAHA-induced apoptosis in only 1/6 SAHA-sensitive MPM cell lines. Analysis of MPM patient samples demonstrated significant inter-patient variations in FLIP and caspase 8 expressions. In addition, SAHA enhanced cisplatin-induced apoptosis in a FLIP-dependent manner.
CONCLUSIONS: These results indicate that FLIP is a major target for SAHA in MPM and identifies FLIP, caspase 8 and associated signalling molecules as candidate biomarkers for SAHA in this disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154545     DOI: 10.1016/j.ejca.2011.11.009

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

Review 1.  Predicting response to epigenetic therapy.

Authors:  Marianne B Treppendahl; Lasse S Kristensen; Kirsten Grønbæk
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

2.  Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.

Authors:  Bohan Yang; Dandan Yu; Jingwen Liu; Kunyu Yang; Gang Wu; Hongli Liu
Journal:  Tumour Biol       Date:  2015-02-04

Review 3.  HDAC inhibitor-based therapies: can we interpret the code?

Authors:  Maria New; Heidi Olzscha; Nicholas B La Thangue
Journal:  Mol Oncol       Date:  2012-10-23       Impact factor: 6.603

4.  Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists.

Authors:  Vera Grinkevitch; Mark Wappett; Nyree Crawford; Daniel B Longley; Ultan McDermott; Simon S McDade; Stacey Price; Andrea Lees; Christopher McCann; Katherine McAllister; Jochen Prehn; Jamie Young; Jess Bateson; Lewis Gallagher; Magali Michaut; Vivek Iyer; Aikaterini Chatzipli; Syd Barthorpe; Daniel Ciznadija; Ido Sloma; Amy Wesa; David A Tice; Lodewyk Wessels; Mathew Garnett
Journal:  Mol Cancer Ther       Date:  2022-04-01       Impact factor: 6.009

5.  Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells.

Authors:  Laura Bergadà; Annabel Sorolla; Andree Yeramian; Nuria Eritja; Cristina Mirantes; Xavier Matias-Guiu; Xavier Dolcet
Journal:  Mol Oncol       Date:  2013-03-28       Impact factor: 6.603

Review 6.  Cancer drug resistance: an evolving paradigm.

Authors:  Caitriona Holohan; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

7.  HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.

Authors:  Wen-Bin Ou; Jiaqing Zhu; Grant Eilers; Xuhui Li; Ye Kuang; Li Liu; Adrián Mariño-Enríquez; Ziqin Yan; Hailong Li; Fanguo Meng; Haimeng Zhou; Qing Sheng; Jonathan A Fletcher
Journal:  Oncotarget       Date:  2015-04-30

8.  Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine.

Authors:  Daniela Schmid; Francois Fay; Donna M Small; Jakub Jaworski; Joel S Riley; Diana Tegazzini; Cathy Fenning; David S Jones; Patrick G Johnston; Daniel B Longley; Christopher J Scott
Journal:  Mol Ther       Date:  2014-07-23       Impact factor: 11.454

9.  Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression.

Authors:  Dario Barbone; Priscilla Cheung; Sailaja Battula; Sara Busacca; Steven G Gray; Daniel B Longley; Raphael Bueno; David J Sugarbaker; Dean A Fennell; V Courtney Broaddus
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

10.  SAHA overcomes FLIP-mediated inhibition of SMAC mimetic-induced apoptosis in mesothelioma.

Authors:  N Crawford; I Stasik; C Holohan; J Majkut; M McGrath; P G Johnston; G Chessari; G A Ward; D J Waugh; D A Fennell; D B Longley
Journal:  Cell Death Dis       Date:  2013-07-18       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.